

Rystiggo (rozanolixizumab-noli)

Disclaimer

Clinical guidelines are developed and adopted to establish evidence-based clinical criteria for utilization management decisions. Clinical guidelines are applicable according to policy and plan type. The Plan may delegate utilization management decisions of certain services to third parties who may develop and adopt their own clinical criteria.

Coverage of services is subject to the terms, conditions, and limitations of a member's policy, as well as applicable state and federal law. Clinical guidelines are also subject to in-force criteria such as the Centers for Medicare & Medicaid Services (CMS) national coverage determination (NCD) or local coverage determination (LCD) for Medicare Advantage plans. Please refer to the member's policy documents (e.g., Certificate/Evidence of Coverage, Schedule of Benefits, Plan Formulary) or contact the Plan to confirm coverage.

Summary

Generalized myasthenia gravis (gMG) is a chronic autoimmune neuromuscular disorder characterized by muscle weakness and fatigue. It is caused by the production of autoantibodies that target components of the neuromuscular junction, such as the acetylcholine receptor (AChR) or muscle-specific tyrosine kinase (MuSK). The condition leads to a breakdown in communication between nerves and muscles, resulting in weakness and fatigue of voluntary muscles.

Symptoms of gMG can vary but commonly include weakness of the eye muscles (ocular myasthenia), drooping eyelids (ptosis), blurred or double vision (diplopia), changes in facial expressions, difficulty swallowing, and shortness of breath. The severity of gMG is often classified using the Myasthenia Gravis Foundation of America (MGFA) Clinical Classification, which categorizes the disease into five main classes (I-V) based on signs, symptoms, and degree of impairment. This classification helps guide treatment decisions and assess disease progression.

Rystiggo (rozanolixizumab-noli), a neonatal Fc receptor blocker, is a prescription medicine indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-AChR or anti-MuSK antibody positive. It is administered through weekly subcutaneous infusions and is designed to target the underlying autoimmune mechanisms of gMG. Management of gMG includes but is not limited to: surgical approaches, cholinesterase inhibitors (e.g., pyridostigmine), immunotherapy (e.g., corticosteroids, azathioprine, mycophenolate mofetil), and intravenous immune globulin. Those with anti-MuSK have been shown to be less responsive to cholinesterase inhibitors, and once started on corticosteroids, often find themselves steroid-dependent despite addition of other therapies. Rystiggo (rozanolixizumab-noli) is the first and only FDA-approved agent for anti-MuSK gMG.

Definitions

"**Generalized myasthenia gravis (gMG)**" is a chronic autoimmune neuromuscular disorder characterized by fluctuating weakness of voluntary muscles.

"**Anti-acetylcholine receptor (anti-AChR) antibodies**" are autoantibodies directed against the nicotinic acetylcholine receptor found at the neuromuscular junction.

"**Anti-muscle specific tyrosine kinase (anti-MuSK) antibodies**" are autoantibodies directed against the muscle-specific tyrosine kinase protein.

"**Cholinesterase inhibitors**" refer to a class of drugs that prevent the breakdown of acetylcholine, a neurotransmitter which plays a major role in memory and muscle movement and contraction.

"**Myasthenia Gravis Foundation of America (MGFA) Clinical Classification**" is a system that categorizes disease severity into five main classes (I-V) with subclasses based on signs, symptoms, and degree of impairment.

"**Myasthenia Gravis Activities of Daily Living (MG-ADL)**" is an 8-item patient-reported questionnaire that assesses daily functions often impacted by myasthenia gravis. Total score ranges from 0 to 24, with a higher score indicating more disability. A positive change in the score indicates worsening and a negative change indicates improvement.

"**Quantitative Myasthenia Gravis (QMG)**" is a comprehensive 13-item scale specifically designed to accurately assess the severity of myasthenia gravis. It evaluates various aspects such as endurance, fatigability, and fluctuations in symptoms. The scale assigns scores ranging from 0 to 39, with higher

scores indicating a more severe manifestation of the disease. A positive change in the score indicates worsening and a negative change indicates improvement.

Medical Necessity Criteria for Initial Authorization

The Plan considers **Rystiggo (rozanolixizumab-noli)** medically necessary when **ALL** of the following criteria are met:

1. Prescribed by or in consultation with a neurologist or neuromuscular disease specialist; **AND**
2. The member is 18 years of age or older; **AND**
3. The member has a confirmed diagnosis of generalized myasthenia gravis (gMG) **AND** documentation of **ALL** of the following:
 - a. Positive serologic test for anti-acetylcholine receptor (anti-AChR) OR anti-muscle specific tyrosine kinase (anti-MuSK) antibodies; **and**
 - b. Myasthenia Gravis Foundation of America (MGFA) Clinical Classification Class II to IVa (see **Appendix, Table 1**); **and**
 - c. Baseline Myasthenia Gravis-Activities of Daily Living (MG-ADL) total score of at least 3 (with at least 3 points from non-ocular symptoms); **AND**
4. **IF** anti-AChR antibody positive, the member is unable to use, limited by toxicity, or has adequately tried and failed or experienced insufficient response to at least **TWO** standard therapies for gMG, such as:
 - a. Cholinesterase inhibitors (eg, pyridostigmine); **and/or**
 - b. Corticosteroids (e.g., prednisone) or inability to taper steroids below a reasonably acceptable level without return of symptoms; **and/or**
 - c. Immunosuppressive therapies (e.g., azathioprine, cyclosporine, mycophenolate mofetil, cyclophosphamide, tacrolimus); **AND**
5. Will not be used concomitantly with other immunomodulatory biologic therapies (e.g., efgartigimod alfa, rituximab, ravulizumab, zilucoplan, etc.); **AND**
6. Prescribed at a dose and frequency that is within FDA approved labeling **OR** is supported by compendia or evidence-based published dosing guidelines for the requested indication.

If the above prior authorization criteria are met, the requested product will be authorized for up to 16-weeks.

Medical Necessity Criteria for Reauthorization

Reauthorization for up to 6 months will be granted if the member has recent (within the last 3 months) clinical chart documentation demonstrating **ALL** of the following criteria:

1. Prescribed by or in consultation with a neurologist or neuromuscular disease specialist; **AND**
2. Documentation of positive clinical response to therapy, such as ANY of the following:
 - a. Improvement in Myasthenia Gravis-Activities of Daily Living (MG-ADL) **OR** Quantitative Myasthenia Gravis (QMG) score from baseline; **and/or**
 - b. Achievement of minimal symptom expression or pharmacological remission; **and/or**
 - c. Lack of relapses or reduced frequency/severity of relapses compared to baseline; **AND**
3. Ongoing therapy is required to maintain disease stability and control; **AND**
4. There is no unacceptable toxicity or adverse reaction to therapy, such as:
 - a. Serious infections (e.g. serious respiratory or urinary tract infections); **and/or**
 - b. Severe hypersensitivity reactions; **and/or**
 - c. Severe immunosuppression; **and/or**
 - d. Other intolerable side effects or reactions; **AND**
5. Will not be used concomitantly with other immunomodulatory biologic therapies (e.g., efgartigimod alfa, rituximab, rozanolixizumab, ravulizumab, zilucoplan, etc.); **AND**
6. Prescribed at a dose and frequency that is within FDA approved labeling **OR** is supported by compendia or evidence-based published dosing guidelines for the requested indication.

Experimental or Investigational / Not Medically Necessary

Rystiggo (rozanolixizumab-noli) for any other indication or use is considered not medically necessary by the Plan, as it is deemed to be experimental, investigational, or unproven. Non-covered indications include, but are not limited to, the following:

- Chronic Inflammatory Demyelinating Polyradiculoneuropathy
- Fibromyalgia
- Leucine-Rich Glioma Inactivated 1 Autoimmune Encephalitis
- Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOG-AD)
- Primary Immune Thrombocytopenia (ITP)
- Thrombocytopenia

Applicable Billing Codes (HCPCS/CPT Codes)

Service(s) name
CPT/HCPCS Codes considered medically necessary if criteria are met:

<i>Code</i>	<i>Description</i>
96369	Subcutaneous infusion for therapy or prophylaxis (specify substance or drug); initial, up to 1 hour, including pump set-up and establishment of subcutaneous infusion site(s)
96371	Subcutaneous infusion for therapy or prophylaxis (specify substance or drug); additional pump set-up with establishment of new subcutaneous infusion site(s) (List separately in addition to code for primary procedure)
96372	Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular
96401	Chemotherapy administration, subcutaneous or intramuscular; non-hormonal anti-neoplastic
J9333	Injection, rozanolixizumab-noli, 1 mg
ICD-10 codes considered medically necessary if criteria are met:	
<i>Code</i>	<i>Description</i>
G70.0	Myasthenia gravis
G70.00	Myasthenia gravis without (acute) exacerbation
G70.01	Myasthenia gravis with (acute) exacerbation
G70.2	Congenital and developmental myasthenia

Appendix

Table 1: Summary of Myasthenia Gravis Foundation of America (MGFA) Disease Clinical Classification

<i>Class</i>	<i>Description</i>
I	Ocular muscle weakness; All other muscles - normal strength
II	Mild generalized weakness
IIa	Predominantly limb/axial weakness; Lesser oropharyngeal involvement possible
IIb	Predominantly oropharyngeal/respiratory weakness; Lesser limb/axial involvement possible

III	Moderate generalized weakness
IIIa	Predominantly limb/axial weakness; Lesser oropharyngeal involvement possible
IIIb	Predominantly oropharyngeal/respiratory weakness; Lesser limb/axial involvement possible
IV	Severe generalized weakness
IVa	Predominantly limb/axial weakness; Lesser oropharyngeal involvement possible
IVb	Predominantly oropharyngeal/respiratory weakness; Lesser limb/axial involvement possible
V	Intubation, with or without ventilation; Not for routine postoperative care

NOTE: The preceding table summarizes key aspects of the Myasthenia Gravis Foundation of America (MGFA) Disease Classifications. This is provided only for quick reference. For the exact definitions and details on the MGFA Disease Classifications, please refer to the original MGFA Classification document available at <https://myasthenia.org/Portals/0/MGFA%20Classification.pdf>.

References

1. Bril V, Benatar M, Andersen H, MG0002 Investigator Study Group, et al. Efficacy and Safety of Rozanolixizumab in Moderate to Severe Generalized Myasthenia Gravis A Phase 2 Randomized Control Trial. *Neurology* Feb 2021, 96 (6) e853-e865; DOI: 10.1212/WNL.0000000000011108.
2. Bril V, Drużdż A, Grosskreutz J, and MG0003 study team. Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study. *Lancet Neurol.* 2023 May;22(5):383-394. doi: 10.1016/S1474-4422(23)00077-7. PMID: 37059507. <https://pubmed.ncbi.nlm.nih.gov/37059507>
3. Bril V, Drużdż A, Grosskreutz J, et al. Long-term Efficacy and Safety of Symptom-driven Cyclic Rozanolixizumab Treatment in Patients with Generalized Myasthenia Gravis: A Pooled Analysis of a Phase 3 Study and Two Open-label Extension Studies (P1-5.012). *Neurology* Apr 2023, 100 (17 Supplement 2) 3747; DOI: 10.1212/WNL.0000000000203497
4. Farrugia ME et al: A practical approach to managing patients with myasthenia gravis-opinions and a review of the literature. *Front Neurol.* 11:604, 2020
5. Gronseth GS et al: Practice advisory: thymectomy for myasthenia gravis (practice parameter update): report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. *Neurology.* 94(16):705-9, 2020
6. Guidon AC, Muppidi S, Nowak RJ, et al. Telemedicine visits in myasthenia gravis: expert guidance and the Myasthenia Gravis Core Exam (MG-CE). *Muscle Nerve* 2021; 64:270-276.
7. Habib AA, Sacconi S, Antonini G, et al. Efficacy and safety of rozanolixizumab in patients with muscle-specific tyrosine kinase autoantibody-positive generalised myasthenia gravis: a subgroup analysis of the randomised, double-blind, placebo-controlled, adaptive phase III MycarinG study. *Ther Adv Neurol Disord.* 2024 Sep 12;17:17562864241273036. doi:10.1177/17562864241273036. eCollection 2024.

8. Jaretzki A 3rd et al: Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. *Neurology*. 55(1):16-23, 2000
9. Jayam-Trouth A, Dabi A, Solieman N, Kurukumbi M, Kalyanam J. Myasthenia gravis: a review. *Autoimmune Dis*. 2012;2012:874680. doi:10.1155/2012/874680.
10. Li J, Wu X, Chu T, et al. The efficacy and safety of FcRN inhibitors in patients with myasthenia gravis: a systematic review and meta-analysis. *J Neurol*. 2024 May; 271(5):2298-2308. doi:10.1007/s00415-024012247-x. Epub 2024 Mar 3.
11. Ma Y, Nie X, Zhu G, et al. The efficacy and safety of different targeted drugs for the treatment of generalized Myasthenia Gravis: a systematic review and bayesian network meta-analysis. *CNS Drugs*. 2024 Feb;38(2):93-104. doi:10.1007/s40263-024-01062-7. Epub 2024 Feb 1.
12. Narayanaswami P, Sanders D, Wolfe G, Benatar M, et al. International consensus guidance for management of myasthenia gravis, 2020 update. *Neurology®* 2021;96:114-122. doi:10.1212/WNL.0000000000001124.
13. Rystiggo (rozanolixizumab) [prescribing information]. Smyrna, GA: UCB Inc; June 2024.
14. Sacca F, Pane C, Espinosa PE, et al. Efficacy and innovative therapies in myasthenia gravis: a systematic review, meta-analysis and network meta-analysis. *Eur J Neurol*. 2023 Dec;30(12):3854-3867. doi:10.1111/ene.15872. Epub 2023 May 30.
15. Sanders DB, Wolfe GI, Benatar M, et al. International consensus guidance for management of myasthenia gravis: executive summary. *Neurology*. 2016;87(4):419-425. doi:10.1212/WNL.00000000000002790
16. Smith AG, Wolfe GI, Habib AI, et al. Risk-benefit analysis of novel treatments for patients with generalized myasthenia gravis. *Adv Ther*. 2024 Dec; 41(12):4628-4647. doi:10.1007/s12325-024-03014-5. Epub 2024 Oct 29.
17. Sussman J et al: The Association of British Neurologists' myasthenia gravis guidelines. *Ann N Y Acad Sci*. 1412(1):166-9, 2018
18. Sussman J, Farrugia ME, Maddison P, et al. Myasthenia gravis: Association of British Neurologists' management guidelines. *Pract Neurol* 2015; 15: 199-206.
19. Zhong H, Li Z, Li X, et al. Initiation response, maximized therapeutic efficacy and post-treatment effects of biological targeted therapies in myasthenia gravis: a systematic review and network meta-analysis. *Front Neurol*. 2024 Oct 28;15:1479685. doi:10.3389/fneur.2024.1479685. eCollection 2024.

Clinical Guideline Revision / History Information

Original Date: 1/26/2024

Reviewed/Revised: 7/1/2025